Chemotherapy (Antivirals): Antiviral Drugs

Introduction / Overview

Antiviral chemotherapy represents a pivotal armamentarium in modern infectious disease management. Viral pathogens, owing to their reliance on host cellular machinery for replication, present unique therapeutic targets that differ markedly from bacterial or fungal agents. The clinical relevance of antiviral agents is underscored by the global burden of diseases such as influenza, human immunodeficiency virus (HIV), hepatitis B and C, herpesviruses, and emerging zoonotic infections. Effective antiviral therapy can reduce morbidity, prevent complications, and in some cases, achieve virologic cure. The rapid evolution of viral resistance and the emergence of new viral threats necessitate continual pharmacologic innovation and a deep understanding of drug action, disposition, and safety.

• Explain the fundamental principles guiding antiviral drug development and classification.
• Describe the pharmacodynamic mechanisms that confer antiviral activity.
• Outline key pharmacokinetic parameters influencing dosing strategies.
• Identify approved therapeutic indications and common off‑label uses.
• Recognize major adverse effects, drug interactions, and special population considerations.

Classification

Drug Classes and Categories

Antiviral agents are traditionally grouped according to the viral family they target and the stage of the viral life cycle they interrupt. The principal categories include:

• Nucleoside/Nucleotide Analogues – Structural mimics of natural nucleosides that terminate DNA or RNA chain elongation.
• Non‑nucleoside Reverse Transcriptase Inhibitors (NNRTIs) – Bind to reverse transcriptase at a distinct site, inducing conformational changes that inhibit polymerase activity.
• Protease Inhibitors – Block viral proteases required for maturation of infectious virions.
• Fusion and Entry Inhibitors – Interfere with viral envelope fusion or attachment to host cell receptors.
• Polymerase Inhibitors (e.g., Neuraminidase Inhibitors) – Target viral polymerases or associated enzymes.
• Immunomodulators – Enhance host antiviral immunity (e.g., interferons).

Chemical Classification

From a chemical standpoint, antiviral agents may be classified as follows:

• Purine and Pyrimidine Analogues – e.g., acyclovir, zidovudine.
• Non‑purine Analogues – e.g., ribavirin, lamivudine.
• Peptide‑Based Inhibitors – e.g., protease inhibitors such as lopinavir/ritonavir.
• Small Molecule Inhibitors – e.g., oseltamivir, tenofovir.
• Biologic Agents – e.g., monoclonal antibodies targeting viral epitopes.

Mechanism of Action

Pharmacodynamics

Antiviral efficacy hinges on selective inhibition of viral replication while sparing host cellular processes. The pharmacodynamic profile of each agent is defined by its potency (IC₅₀), therapeutic index, and the viral target’s susceptibility.

Receptor Interactions

Many antivirals require activation by viral or host enzymes. For instance, nucleoside analogues are phosphorylated by viral thymidine kinase or host kinases to their active triphosphate forms, which then compete with natural nucleotides for incorporation into viral nucleic acids. NNRTIs bind allosteric sites on reverse transcriptase, whereas fusion inhibitors engage the viral envelope glycoprotein gp41, preventing the conformational change necessary for membrane fusion.

Molecular/Cellular Mechanisms

Once activated, nucleoside analogues are incorporated into viral DNA or RNA, resulting in chain termination or lethal mutagenesis. Protease inhibitors bind to the catalytic cleft of the viral protease, blocking cleavage of polyproteins into functional viral proteins. Neuraminidase inhibitors, such as oseltamivir, competitively inhibit the viral neuraminidase enzyme, impeding release of progeny virions from infected cells. Immunomodulators, notably interferons, upregulate antiviral gene expression and enhance natural killer cell activity.

Pharmacokinetics

Absorption

Oral bioavailability varies widely among antiviral agents. Acyclovir exhibits low oral absorption (~10–30%), whereas tenofovir disoproxil fumarate demonstrates improved bioavailability (~25–30%). Intravenous formulations bypass first‑pass metabolism and provide rapid therapeutic levels, essential in severe infections.

Distribution

Volume of distribution (V_d) is influenced by lipophilicity and plasma protein binding. Highly lipophilic agents such as lopinavir/ritonavir penetrate tissues and the central nervous system, while hydrophilic analogues may have limited tissue penetration. Protein binding ranges from 20–90%, affecting free drug concentrations and drug‑drug interaction potential.

Metabolism

Metabolic pathways include hepatic cytochrome P450 (CYP) oxidation, glucuronidation, and dephosphorylation. NNRTIs such as efavirenz undergo CYP3A4 metabolism, whereas nucleoside analogues are primarily excreted unchanged. Ritonavir acts as a potent CYP3A4 inhibitor, boosting plasma levels of co‑administered protease inhibitors.

Excretion

Renal excretion dominates for many nucleoside analogues. Clearance (CL) is often linear and dose‑dependent, with renal impairment necessitating dose adjustments. Hepatic excretion is significant for protease inhibitors and some fusion inhibitors.

Half‑Life and Dosing Considerations

Half‑life (t_1/2) ranges from hours for ribavirin to days for long‑acting agents such as tenofovir alafenamide. Dosing schedules are tailored to maintain trough concentrations above the effective concentration (EC₅₀) while minimizing toxicity. Therapeutic drug monitoring may be required for agents with narrow therapeutic windows, such as protease inhibitors.

Therapeutic Uses / Clinical Applications

Approved Indications

Approved antiviral therapies encompass a broad spectrum of viral infections:

• HIV – Combination antiretroviral therapy (cART) including nucleoside reverse transcriptase inhibitors, NNRTIs, protease inhibitors, integrase strand transfer inhibitors, and entry inhibitors.
• Hepatitis B – Tenofovir disoproxil fumarate, tenofovir alafenamide, entecavir.
• Hepatitis C – Direct‑acting antiviral (DAA) regimens such as sofosbuvir/ledipasvir, glecaprevir/pibrentasvir.
• Herpesviruses – Acyclovir, valacyclovir, famciclovir for HSV and VZV; ganciclovir for CMV.
• Influenza – Neuraminidase inhibitors (oseltamivir, zanamivir, peramivir).
• Respiratory syncytial virus (RSV) – Ribavirin in severe cases.
• Human papillomavirus (HPV) – Imiquimod (topical immunomodulator).

Off‑Label Uses

Several antiviral agents are employed off‑label to address unmet clinical needs. For example, ribavirin is used in severe respiratory viral infections, such as SARS‑CoV‑2, despite limited evidence. Lamivudine has been utilized in chronic hepatitis B patients with inadequate response to other nucleoside analogues. Acyclovir is occasionally prescribed for prophylaxis of HSV reactivation in immunocompromised patients beyond the standard indications.

Adverse Effects

Common Side Effects

Side effect profiles are largely agent‑specific:

• Acyclovir – Gastrointestinal upset, rash, rare neurotoxicity.
• Tenofovir – Renal tubular dysfunction, osteopenia.
• Ribavirin – Hemolytic anemia, teratogenicity.
• Efavirenz – Neuropsychiatric manifestations (dizziness, vivid dreams).
• Oseltamivir – Nausea, vomiting, neuropsychiatric events in pediatric populations.

Serious / Rare Adverse Reactions

Serious reactions may include hypersensitivity reactions (e.g., Stevens–Johnson syndrome with acyclovir), severe hepatotoxicity (e.g., with certain protease inhibitors), and severe anemia with ribavirin. Rare but life‑threatening complications such as interstitial lung disease with ribavirin and nephrotoxicity with ganciclovir have been documented.

Black Box Warnings

Ribavirin carries a black box warning for teratogenicity. Protease inhibitors may have warnings related to cardiovascular risk and hepatotoxicity. Agents requiring monitoring of blood counts or renal function are also accompanied by appropriate warnings.

Drug Interactions

Major Drug‑Drug Interactions

Interaction potential is high for antivirals that are substrates or inhibitors of CYP enzymes:

• Ritonavir – Potentiates plasma levels of protease inhibitors, CYP3A4 substrates.
• Efavirenz – Induces CYP3A4, reducing levels of co‑administered drugs such as statins and oral contraceptives.
• Tenofovir – May interact with nephrotoxic agents (e.g., aminoglycosides). Concomitant use of high‑dose steroids can increase the risk of bone loss.

Contraindications

Contraindications include severe hepatic impairment for agents primarily metabolized by the liver (e.g., lopinavir/ritonavir) and severe renal impairment for drugs with predominant renal clearance (e.g., acyclovir, ganciclovir). Contraindications also arise from hypersensitivity histories and known drug hypersensitivity syndromes.

Special Considerations

Use in Pregnancy / Lactation

Pregnancy risk categories vary. Acyclovir is considered category B, whereas ribavirin is category X. Tenofovir disoproxil fumarate is category B but is preferred over tenofovir alafenamide due to lower bone toxicity. Lactation considerations hinge on drug excretion into breast milk; most nucleoside analogues are excreted in minimal amounts, yet caution is advised.

Pediatric / Geriatric Considerations

Pediatric dosing requires weight‑based calculations and careful monitoring for growth suppression with tenofovir. Geriatric patients often present with comorbidities and polypharmacy, increasing interaction risk. Dose adjustments for renal function are imperative in both populations.

Renal / Hepatic Impairment

Renal dosing guidelines are well established for nucleoside analogues, with dose reductions proportional to creatinine clearance. Hepatic impairment may necessitate avoidance or dose modification for drugs with significant hepatic metabolism. Therapeutic drug monitoring is recommended for agents with narrow therapeutic indices in these populations.

Summary / Key Points

Bullet Point Summary

• Antiviral chemotherapy targets specific stages of the viral life cycle, enabling selective inhibition of viral replication.
• Pharmacokinetic properties—absorption, distribution, metabolism, and excretion—dictate dosing regimens and influence drug interactions.
• Approved indications cover a wide range of viral diseases, with off‑label uses expanding as new evidence emerges.
• Adverse effect profiles vary by class; teratogenicity, nephrotoxicity, and neuropsychiatric events are common concerns.
• Drug interactions, particularly involving CYP enzymes, require vigilant review of concomitant medications.
• Special populations—including pregnant patients, children, the elderly, and those with renal or hepatic impairment—demand individualized dosing and monitoring strategies.

Clinical Pearls

• Ensure adequate patient counseling regarding adherence and potential side effects to optimize therapeutic outcomes.
• Monitor renal function closely when prescribing nucleoside analogues to prevent cumulative toxicity.
• Consider therapeutic drug monitoring for protease inhibitors in patients with significant drug‑drug interaction potential.
• Screen for pre‑existing hepatitis B before initiating tenofovir or other nucleoside analogues to prevent reactivation.
• Employ prophylactic antiviral therapy judiciously in high‑risk immunocompromised populations to prevent opportunistic viral reactivation.

References

1. Gilbert DN, Chambers HF, Saag MS, Pavia AT. The Sanford Guide to Antimicrobial Therapy. 53rd ed. Sperryville, VA: Antimicrobial Therapy Inc; 2023.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.